Search

Your search keyword '"Pisano, Giuseppina"' showing total 49 results
Start Over Author "Pisano, Giuseppina"
49 results on '"Pisano, Giuseppina"'

1. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

Author

Lombardi, Rosa, Colavolpe, Lucia, Alletto, Francesca, Cespiati, Annalisa, Fatta, Erika, Bertelli, Cristina, Cinque, Felice, Pisano, Giuseppina, Pulixi, Edoardo, Francione, Paolo, Maffi, Gabriele, Iuculano, Federica, Dongiovanni, Paola, Meroni, Marica, Burdick, Larry, Bignamini, Daniela, Maggioni, Marco, Valenti, Luca, Fargion, Silvia, and Fracanzani, Anna Ludovica

Published
2024
Full Text
View/download PDF

2. FRI-248-YI The impact of baseline sarcopenia, over time, on liver and cardiovascular damage in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): a prospective study

Author

Santomenna, Floriana, primary, Cespiati, Annalisa, additional, Carlomagno, Matteo, additional, Oberti, Giovanna, additional, Pulixi, Edoardo, additional, Currà, Jaqueline, additional, Smith, Daniel, additional, Lombardi, Rosa, additional, Fatta, Erika, additional, Bertelli, Cristina, additional, Pisano, Giuseppina, additional, and Fracanzani, Anna Ludovica, additional

Published
2024
Full Text
View/download PDF

3. FRI-207-YI Sarcopenia in metabolic-dysfunction associated steatotic liver disease (MASLD): unraveling its role in cardiovascular damage

Author

Cespiati, Annalisa, primary, Lombardi, Rosa, additional, Sigon, Giordano, additional, Santomenna, Floriana, additional, Carlomagno, Matteo, additional, Couffon, Margaux, additional, Martino, Beatrice, additional, Huang, Jian, additional, Smith, Daniel, additional, Pisano, Giuseppina, additional, Oberti, Giovanna, additional, Forlano, Roberta, additional, Manousou, Pinelopi, additional, Petta, Salvatore, additional, and Fracanzani, Anna Ludovica, additional

Published
2024
Full Text
View/download PDF

4. FRI-226 The impact of light to moderate alcohol consumption on liver and cardiovascular damage in metabolic-dysfunction associated steatotic liver disease

Author

Lombardi, Rosa, primary, Cinque, Felice, additional, Dalbeni, Andrea, additional, Cespiati, Annalisa, additional, Santomenna, Floriana, additional, Currà, Jaqueline, additional, Smith, Daniel, additional, Fatta, Erika, additional, Bertelli, Cristina, additional, Pisano, Giuseppina, additional, Pulixi, Edoardo, additional, Mantovani, Anna, additional, Zoncapè, Mirko, additional, Sacerdoti, David, additional, and Fracanzani, Anna Ludovica, additional

Published
2024
Full Text
View/download PDF

5. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

Author

Cespiati, Annalisa, Petta, Salvatore, Lombardi, Rosa, Di Marco, Vito, Calvaruso, Vincenza, Bertelli, Cristina, Pisano, Giuseppina, Fatta, Erika, Sigon, Giordano, Iuculano, Federica, Crapanzano, Luciano, Gibilaro, Gerlando, Francione, Paolo, Craxì, Antonio, Fargion, Silvia, and Fracanzani, Anna Ludovica

Published
2021
Full Text
View/download PDF

8. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades

Author

Lombardi, Rosa, primary, Colavolpe, Lucia, additional, Alletto, Francesca, additional, Cespiati, Annalisa, additional, Fatta, Erika, additional, Bertelli, Cristina, additional, Cinque, Felice, additional, Pisano, Giuseppina, additional, Pulixi, Edoardo, additional, Francione, Paolo, additional, Maffi, Gabriele, additional, Iuculano, Federica, additional, Dongiovanni, Paola, additional, Burdick, Larry, additional, Bignamini, Daniela, additional, Maggioni, Marco, additional, Valenti, Luca, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2023
Full Text
View/download PDF

10. SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Author

Lombardi, Rosa, primary, Mantovani, Alessandro, additional, Cespiati, Annalisa, additional, Maffi, Gabriele, additional, Del Zanna, Elena, additional, Francione, Paolo, additional, Cinque, Felice, additional, Villani, Rosanna, additional, Passigato, Nicola, additional, Orsi, Emanuela, additional, Grancini, Valeria, additional, Pisano, Giuseppina, additional, Maffeis, Claudio, additional, Bignamini, Daniela, additional, Serviddio, Gaetano, additional, Targher, Giovanni, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2023
Full Text
View/download PDF

13. Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity

Author

Cinque, Felice, primary, Lombardi, Rosa, additional, Cespiati, Annalisa, additional, Francione, Paolo, additional, Fatta, Erika, additional, Bertelli, Cristina, additional, Pisano, Giuseppina, additional, Oberti, Giovanna, additional, Colavolpe, Lucia, additional, Alletto, Francesca, additional, Dongiovanni, Paola, additional, Meroni, Marica, additional, Bozzi, Giorgio, additional, Bandera, Alessandra, additional, and Fracanzani, Anna Ludovica, additional

Published
2022
Full Text
View/download PDF

14. The rs599839 A&gt

Author

Meroni, Marica, Longo, Miriam, Paolini, Erika, Alisi, Anna, Miele, Luca, Caro, Emilia Rita De, Pisano, Giuseppina, Maggioni, Marco, Soardo, Giorgio, Valenti, Luca Vittorio, Fracanzani, Anna Ludovica, and Dongiovanni, Paola

Subjects
NAFLD, genetic variants, lipid metabolism, nutritional and metabolic diseases, PSRC1, HCC, digestive system diseases
Abstract

Background and Aims: Dyslipidemia and cardiovascular diseases (CVD) are comorbidities of nonalcoholic fatty liver disease (NAFLD), which ranges from steatosis to hepatocellular carcinoma (HCC). The rs599839 A&gt, G variant, in the CELSR2-PSRC1-SORT1 gene cluster, has been associated CVD, but its impact on metabolic traits and on the severity liver damage in NAFLD has not been investigated yet. Methods: We evaluated the effect of the rs599839 variant in 1426 NAFLD patients (Overall cohort) of whom 131 had HCC (NAFLD-HCC), in 500,000 individuals from the UK Biobank Cohort (UKBBC), and in 366 HCC samples from The Cancer Genome Atlas (TCGA). Hepatic PSRC1, SORT1 and CELSR2 expressions were evaluated by RNAseq (n = 125). Results: The rs599839 variant was associated with reduced circulating LDL, carotid intima-media thickness, carotid plaques and hypertension (p &lt, 0.05) in NAFLD patients and with protection against dyslipidemia in UKBBC. The minor G allele was associated with higher risk of HCC, independently of fibrosis severity (odds ratio (OR): 5.62, 95% c.i. 1.77–17.84, p = 0.003), poor prognosis and advanced tumor stage (p &lt, 0.05) in the overall cohort. Hepatic PSRC1, SORT1 and CELSR2 expressions were increased in NAFLD patients carrying the rs599839 variant (p &lt, 0.0001). SORT1 mRNA levels negatively correlated with circulating lipids and with those of genes involved in lipoprotein turnover (p &lt, 0.0001). Conversely, PSRC1 expression was positively related to that of genes implicated in cell proliferation (p &lt, 0.0001). In TCGA, PSRC1 over-expression promoted more aggressive HCC development (p &lt, 0.05). Conclusions: In sum, the rs599839 A&gt, G variant is associated with protection against dyslipidemia and CVD in NAFLD patients, but as one it might promote HCC development by modulating SORT1 and PSRC1 expressions which impact on lipid metabolism and cell proliferation, respectively.

Published
2021
Full Text
View/download PDF

15. The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients

Author

Meroni, Marica, Longo, Miriam, Paolini, Erika, Alisi, Anna, Miele, Luca, De Caro, Emilia Rita, Pisano, Giuseppina, Maggioni, Marco, Soardo, Giorgio, Valenti, Luca Vittorio, Fracanzani, Anna Ludovica, Dongiovanni, Paola, Miele, Luca (ORCID:0000-0003-3464-0068), Meroni, Marica, Longo, Miriam, Paolini, Erika, Alisi, Anna, Miele, Luca, De Caro, Emilia Rita, Pisano, Giuseppina, Maggioni, Marco, Soardo, Giorgio, Valenti, Luca Vittorio, Fracanzani, Anna Ludovica, Dongiovanni, Paola, and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

Simple SummaryDyslipidemia is a hallmark of nonalcoholic fatty liver disease (NAFLD) and the rs599839 variant in the CELSR2-PSRC1-SORT1 genetic cluster, has been associated with a protection against cardiovascular events. Here, we revealed a novel link between the rs599839 variant and hepatocellular carcinoma (HCC) whose onset in the context of NAFLD is rapidly increasing. We found that the rs599839 variant disentangled the risk of HCC from that of cardiovascular abnormalities by modulating SORT1 and PSRC1 expressions. The latter emerged as a potential modifier of liver carcinogenesis.Background and Aims: Dyslipidemia and cardiovascular diseases (CVD) are comorbidities of nonalcoholic fatty liver disease (NAFLD), which ranges from steatosis to hepatocellular carcinoma (HCC). The rs599839 A>G variant, in the CELSR2-PSRC1-SORT1 gene cluster, has been associated CVD, but its impact on metabolic traits and on the severity liver damage in NAFLD has not been investigated yet. Methods: We evaluated the effect of the rs599839 variant in 1426 NAFLD patients (Overall cohort) of whom 131 had HCC (NAFLD-HCC), in 500,000 individuals from the UK Biobank Cohort (UKBBC), and in 366 HCC samples from The Cancer Genome Atlas (TCGA). Hepatic PSRC1, SORT1 and CELSR2 expressions were evaluated by RNAseq (n = 125). Results: The rs599839 variant was associated with reduced circulating LDL, carotid intima-media thickness, carotid plaques and hypertension (p < 0.05) in NAFLD patients and with protection against dyslipidemia in UKBBC. The minor G allele was associated with higher risk of HCC, independently of fibrosis severity (odds ratio (OR): 5.62; 95% c.i. 1.77-17.84, p = 0.003), poor prognosis and advanced tumor stage (p < 0.05) in the overall cohort. Hepatic PSRC1, SORT1 and CELSR2 expressions were increased in NAFLD patients carrying the rs599839 variant (p < 0.0001). SORT1 mRNA levels negatively correlated with circulating lipids and with those of genes involved in lipoprot

Published
2021

16. A long story begun with a simple sore throat

Author

Pisano, Giuseppina, Bonara, Paola, Rietti, Paolo, Airaghi, Lorena, Sinigaglia, Luigi, Boccoli, Giovanni, Burdick, Larry, del Medico, Marta, Pulixi, Edoardo, Silini, Fabio, Gandolfi, Alessandra, and Fargion, Silvia

Published
2010
Full Text
View/download PDF

18. The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients

Author

Meroni, Marica, primary, Longo, Miriam, additional, Paolini, Erika, additional, Alisi, Anna, additional, Miele, Luca, additional, De Caro, Emilia Rita, additional, Pisano, Giuseppina, additional, Maggioni, Marco, additional, Soardo, Giorgio, additional, Valenti, Luca Vittorio, additional, Fracanzani, Anna Ludovica, additional, and Dongiovanni, Paola, additional

Published
2021
Full Text
View/download PDF

19. FRI-474 - SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: a five-year follow-up study

Author

Lombardi, Rosa, Mantovani, Alessandro, Cespiati, Annalisa, Maffi, Gabriele, Del Zanna, Elena, Francione, Paolo, Cinque, Felice, Villani, Rosanna, Passigato, Nicola, Orsi, Emanuela, Grancini, Valeria, Pisano, Giuseppina, Maffeis, Claudio, Bignamini, Daniela, Serviddio, Gaetano, Targher, Giovanni, Fargion, Silvia, and Fracanzani, Anna Ludovica

Published
2023
Full Text
View/download PDF

22. NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes

Author

Lombardi, Rosa, primary, Airaghi, Lorena, additional, Targher, Giovanni, additional, Serviddio, Gaetano, additional, Maffi, Gabriele, additional, Mantovani, Alessandro, additional, Maffeis, Claudio, additional, Colecchia, Antonio, additional, Villani, Rosanna, additional, Rinaldi, Luca, additional, Orsi, Emanuela, additional, Pisano, Giuseppina, additional, Adinolfi, Luigi Elio, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2020
Full Text
View/download PDF

23. NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients

Author

Lombardi, Rosa, primary, Airaghi, Lorena, additional, Targher, Giovanni, additional, Serviddio, Gaetano, additional, Maffi, Gabriele, additional, Mantovani, Alessandro, additional, Maffeis, Claudio, additional, Colecchia, Antonio, additional, Villani, Rosanna, additional, Rinaldi, Luca, additional, Orsi, Emanuela, additional, Pisano, Giuseppina, additional, Adinolfi, Luigi Elio, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2020
Full Text
View/download PDF

24. Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis

Author

Sigon, Giordano, primary, Cespiati, Annalisa, additional, Pisano, Giuseppina, additional, D’Ambrosio, Roberta, additional, Clerici, Marigrazia, additional, Chantarangkul, Veena, additional, Lampertico, Pietro, additional, Sollazzi, Roberta, additional, Peyvandi, Flora, additional, Tripodi, Armando, additional, Lombardi, Rosa, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2020
Full Text
View/download PDF

27. Registro Italiano Fibrosi cistica Rapporto 2011-2014

Author

Giordani, Barbara, Amato, Annalisa, Majo, Fabio, Ferrari, Gianluca, Quattrucci, Serena, Minicucci, Laura, Padoan, Rita, Floridia, Giovanna, Fornaro, Gianna Puppo, Taruscio, Domenica, Salvatore, Marco, Albera, Carlo, Angiolillo, Antonella, Assael, Baroukh Maurice, Baldo, Ermanno, Battistini, Fiorella, Bena, Cristina, Bernardi, Maria Grazia, Bertasi, Serenella, Bignamini, Elisabetta, Bisogno, Arianna, Braggion, Cesare, Cannata, Loredana, Carnicella, Angela, Carnovale, Vincenzo, Ciciretti, Maria Antonietta, Cirilli, Natalia, Collura, Mirella, Colombo, Carla, Cucchiara, Salvatore, Di Sabatino, Maria, Di Stefano, Eliana, Ficili, Francesca, Francalanci, Michela, Gagliardini, Rolando, Iansa, Patrizia, Laezza, Caterina, La Rosa, Mario, Leonardi, Salvatore, Lucanto, Maria Cristina, Lucidi, Vincenzina, Macchiaroli, Anna Maria, Magazzù, Giuseppe, Manca, Antonio, Mascotto, Daniela, Mencarini, Valeria, Moretti, Paolo, Negri, Amalia, Palladino, Nicola, Pintani, Emily, Pisano, Giuseppina, Pisi, Giovanna, Pizzamiglio, Giovanna, Poli, Furio, Raia, Valeria, Ratclif, Luigi, Ros, Mirco, Rotolo, Novella, Salvatore, Donatello, Spaggiari, Cinzia, Tonelli, Tiziana, Tuccio, Giuseppe, and Zavataro, Lucia

Subjects
BMI, CF referral centre, Registry, CF support centre, Epidemiology, [delta]F508, Environmental and Occupational Health, Cystic fibrosis, FEV, Public Health, Environmental and Occupational Health, Public Health
Published
2018

28. Liver fibrosis by FibroScan ® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes

Author

Lombardi, Rosa, primary, Airaghi, Lorena, additional, Targher, Giovanni, additional, Serviddio, Gaetano, additional, Maffi, Gabriele, additional, Mantovani, Alessandro, additional, Maffeis, Claudio, additional, Colecchia, Antonio, additional, Villani, Rosanna, additional, Rinaldi, Luca, additional, Orsi, Emanuela, additional, Pisano, Giuseppina, additional, Adinolfi, Luigi E., additional, Fargion, Silvia, additional, and Fracanzani, Anna L., additional

Published
2019
Full Text
View/download PDF

29. Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis

Author

Sigon, Giordano, primary, D'Ambrosio, Roberta, additional, Clerici, Mariagrazia, additional, Pisano, Giuseppina, additional, Chantarangkul, Veena, additional, Sollazzi, Roberta, additional, Lombardi, Rosa, additional, Peyvandi, Flora, additional, Lampertico, Pietro, additional, Fargion, Silvia, additional, Tripodi, Armando, additional, and Fracanzani, Anna Ludovica, additional

Published
2019
Full Text
View/download PDF

30. FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage

Author

Sigon, Giordano, primary, Pisano, Giuseppina, additional, D’ambrosio, Roberta, additional, Clerici, Mariagrazia, additional, Chantarangkul, Veena, additional, Lampertico, Pietro, additional, Sollazzi, Roberta, additional, Peyvandi, Flora, additional, Tripodi, Armando, additional, Fargion, Silvia, additional, and Fracanzani, Anna Ludovica, additional

Published
2019
Full Text
View/download PDF

31. Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

Author

Lombardi, Rosa, Airaghi, Lorena, Targher, Giovanni, Serviddio, Gaetano, Maffi, Gabriele, Mantovani, Alessandro, Maffeis, Claudio, Colecchia, Antonio, Villani, Rosanna, Rinaldi, Luca, Orsi, Emanuela, Pisano, Giuseppina, Adinolfi, Luigi E., Fargion, Silvia, and Fracanzani, Anna L.

Subjects
TYPE 2 diabetes, FATTY liver, FIBROSIS, LIVER, CARDIOVASCULAR diseases
Abstract

Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan®, correlates with chronic vascular complications in a cohort of T2DM. Methods: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. Results: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication, 19% a macrovascular complication (prior myocardial infarction and/or ischaemic stroke) and 33% a microvascular one (26% chronic kidney disease [CKD]; 16% retinopathy; 6% neuropathy). In all, 171 (72%) patients had CAP ≥ 248dB/m (ie hepatic steatosis), whereas 83 (21%) patients had LSM ≥ 7.0/6.2 kPa (M/XL probes) (significant liver fibrosis). CAP was not associated with any macro/microvascular complications, whereas LSM ≥ 7.0/6.2 kPa was independently associated with prior cardiovascular disease (adjusted OR 3.3, 95%CI 1.2‐8.8; P =.02) and presence of microvascular complications (adjusted OR 4.2, 95%CI 1.5‐11.4; P =.005), mainly CKD (adjusted OR 3.6, 95%CI 1.3‐10.1; P =.01) and retinopathy (adjusted OR 3.7, CI 95% 1.2‐11.9; P =.02). Neither diabetes duration nor haemoglobin A1c differed according to CAP or LSM values. Conclusion: Significant fibrosis, detected by FibroScan®, is independently associated with increased prevalence of macrovascular and microvascular complications, thus opening a new scenario in the use of this tool for a comprehensive evaluation of hepatic and vascular complications in patients with T2DM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

33. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease

Author

Fracanzani, Anna Ludovica, primary, Pisano, Giuseppina, additional, Consonni, Dario, additional, Tiraboschi, Silvia, additional, Baragetti, Andrea, additional, Bertelli, Cristina, additional, Norata, Giuseppe Danilo, additional, Dongiovanni, Paola, additional, Valenti, Luca, additional, Grigore, Liliana, additional, Tonella, Tatiana, additional, Catapano, Alberico, additional, and Fargion, Silvia, additional

Published
2016
Full Text
View/download PDF

39. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice

Author

Costantino, Giorgio, primary, Rusconi, Anna Maria, additional, Duca, Pier Giorgio, additional, Guzzetti, Stefano, additional, Bossi, Ilaria, additional, Del Medico, Marta, additional, Pisano, Giuseppina, additional, Bulgheroni, Mara, additional, Solbiati, Monica, additional, Furlan, Raffaello, additional, and Montano, Nicola, additional

Published
2008
Full Text
View/download PDF

41. SAN FRANCISCO SYNCOPE RULE, OESIL RISK SCORE AND CLINICAL JUDGMENT IN THE ASSESSMENT OF SHORT TERM OUTCOME OF SYNCOPE

Author

Dipaola, Franca, primary, Costantino, Giorgio, additional, Perego, Francesca, additional, Borella, Marta, additional, Galli, Andrea, additional, Cantoni, Giulia, additional, Pisano, Giuseppina, additional, Barbic, Franca, additional, Casella, Francesco, additional, Duca, Pier Giorgio, additional, and Furlan, Raffaello, additional

Published
2008
Full Text
View/download PDF

42. Unusual presentation in a case of primary hyperparathyroidism.

Author

Airaghi, Lorena, Pisano, Giuseppina, Pulixi, Edoardo, Benti, Riccardo, and Baldini, Marina

Abstract

This report describes a case of classic severe primary hyperparathyroidism (PH) with clinical presentation that is very infrequent nowadays, which was osteitis fibrosa cystica. As bone scintigraphy demonstrated multiple areas of increasing uptake associated with hypercalcemia, a thorough investigation was conducted to exclude the neoplasms which most frequently are responsible for bone secondarisms. A fludeoxyglucose (FDG) positron emission tomography/CT demonstrated diffuse and multiple foci of increased FDG uptake and a focal uptake at the left thyroid region. Parathyroid function was studied, revealing unexpectedly high parathyroid hormone (PTH) levels. Further tests confirmed the diagnosis of PH and localized a parathyroid adenoma in the lower left side. [ABSTRACT FROM AUTHOR]

Published
2011

43. FRI433 - Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis.

Author

Sigon, Giordano, Cespiati, Annalisa, Pisano, Giuseppina, D'Ambrosio, Roberta, Clerici, Marigrazia, Chantarangkul, Veena, Lampertico, Pietro, Sollazzi, Roberta, Peyvandi, Flora, Tripodi, Armando, Lombardi, Rosa, Fargion, Silvia, and Fracanzani, Anna Ludovica

Subjects
*CHRONIC hepatitis C, *ANTIVIRAL agents, *LIVER, *FIBROSIS
Published
2020
Full Text
View/download PDF

44. NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes

Author

Claudio Maffeis, Anna Ludovica Fracanzani, Giovanni Targher, Giuseppina Pisano, Emanuela Orsi, Gabriele Maffi, Alessandro Mantovani, Rosanna Villani, Antonio Colecchia, Rosa Lombardi, Gaetano Serviddio, Luigi Elio Adinolfi, Silvia Fargion, Luca Rinaldi, Lorena Airaghi, Lombardi, Rosa, Airaghi, Lorena, Targher, Giovanni, Serviddio, Gaetano, Maffi, Gabriele, Mantovani, Alessandro, Maffeis, Claudio, Colecchia, Antonio, Villani, Rosanna, Rinaldi, Luca, Orsi, Emanuela, Pisano, Giuseppina, Adinolfi, Luigi Elio, Fargion, Silvia, Fracanzani, Anna Ludovica, Lombardia, Rosa, Airaghia, Lorena, Maffia, Gabriele, Villanic, Rosanna, Emanuela Orsi, F, Fargiona, Silvia, and Ludovica Fracanzani, Anna

Subjects
Liver Cirrhosis, medicine.medical_specialty, Diabetic neuropathy, Microvascular complications, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Gastroenterology, NAFLDNon-invasive diagnosisStrokeMicrovascular complicationsType 2 diabetes screeningDiabetic neuropathy, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Non-alcoholic Fatty Liver Disease, Fibrosis score, Internal medicine, Diabetes mellitus, NAFLD, Non-invasive diagnosis, Internal Medicine, medicine, Ambulatory Care, Humans, Stroke, business.industry, Non-invasive diagnosi, Type 2 diabetes screening, medicine.disease, Peripheral neuropathy, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Microvascular complication, Steatosis, Hepatic fibrosis, business
Abstract

We demonstrate in 351 diabetic patients with steatosis that NAFLD fibrosis score (NFS), a rapid and affordable score to diagnose hepatic fibrosis, identifies patients at higher risk of advanced fibrosis and vascular diabetic complications (especially peripheral neuropathy), pointing NFS as a first-line vascular and hepatic screening in diabetic patients. (C) 2020 Elsevier Inc. All rights reserved.

Published
2020

45. FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

Author

Carlo Acierno, Paola Dongiovanni, Antonio Craxì, Rosa Lombardi, Giuseppina Pisano, Anna Ludovica Fracanzani, Luigi Elio Adinolfi, Federica Spatola, Roberta Boemi, Silvia Fargion, Luca Rinaldi, Salvatore Petta, Luca Valenti, Lombardi, R, Petta, S, Pisano, G, Dongiovanni, P, Rinaldi, L, Adinolfi, Le, Acierno, C, Valenti, L, Boemi, R, Spatola, F, Craxì, A, Fargion, S, Fracanzani, Al, Lombardi, Rosa, Petta, Salvatore, Pisano, Giuseppina, Dongiovanni, Paola, Rinaldi, Luca, Adinolfi, Luigi Elio, Acierno, Carlo, Valenti, Luca, Boemi, Roberta, Spatola, Federica, Craxì, Antonio, Fargion, Silvia, and Fracanzani, Anna Ludovica

Subjects
Liver Cirrhosis, Nonalcoholic steatohepatitis, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine.disease, Fibrosis, digestive system diseases, NASH, FIBROSCAN, CARDIOVASCULAR, Liver, Non-alcoholic Fatty Liver Disease, cardiovascular disease, Internal medicine, NAFLD, Nonalcoholic fatty liver disease, medicine, Elasticity Imaging Techniques, Humans, type 2 diabetes, business, liver stiffness measurement, microvascular complication
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan® , correlates with chronic vascular complications in a cohort of T2DM. METHODS: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. RESULTS: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication, 19% a macrovascular complication (prior myocardial infarction and/or ischaemic stroke) and 33% a microvascular one (26% chronic kidney disease [CKD]; 16% retinopathy; 6% neuropathy). In all, 171 (72%) patients had CAP ≥ 248dB/m (ie hepatic steatosis), whereas 83 (21%) patients had LSM ≥ 7.0/6.2 kPa (M/XL probes) (significant liver fibrosis). CAP was not associated with any macro/microvascular complications, whereas LSM ≥ 7.0/6.2 kPa was independently associated with prior cardiovascular disease (adjusted OR 3.3, 95%CI 1.2-8.8; P = .02) and presence of microvascular complications (adjusted OR 4.2, 95%CI 1.5-11.4; P = .005), mainly CKD (adjusted OR 3.6, 95%CI 1.3-10.1; P = .01) and retinopathy (adjusted OR 3.7, CI 95% 1.2-11.9; P = .02). Neither diabetes duration nor haemoglobin A1c differed according to CAP or LSM values. CONCLUSION: Significant fibrosis, detected by FibroScan® , is independently associated with increased prevalence of macrovascular and microvascular complications, thus opening a new scenario in the use of this tool for a comprehensive evaluation of hepatic and vascular complications in patients with T2DM.

Published
2020

46. THU050 - NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients.

Author

Lombardi, Rosa, Airaghi, Lorena, Targher, Giovanni, Serviddio, Gaetano, Maffi, Gabriele, Mantovani, Alessandro, Maffeis, Claudio, Colecchia, Antonio, Villani, Rosanna, Rinaldi, Luca, Orsi, Emanuela, Pisano, Giuseppina, Adinolfi, Luigi Elio, Fargion, Silvia, and Fracanzani, Anna Ludovica

Subjects
*PEOPLE with diabetes, *FATTY liver, *FIBROSIS, *LIVER, *LIVER histology
Published
2020
Full Text
View/download PDF

47. Liver fibrosis by FibroScan ® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

Author

Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffeis C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, and Fracanzani AL

Subjects
Heart Disease Risk Factors, Humans, Liver Cirrhosis diagnostic imaging, Risk Factors, Brain Ischemia, Cardiovascular Diseases, Diabetes Mellitus, Type 2 complications, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease diagnostic imaging, Stroke
Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan ® , correlates with chronic vascular complications in a cohort of T2DM., Methods: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan ® and extensive evaluation of macrovascular and microvascular diabetic complications., Results: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication, 19% a macrovascular complication (prior myocardial infarction and/or ischaemic stroke) and 33% a microvascular one (26% chronic kidney disease [CKD]; 16% retinopathy; 6% neuropathy). In all, 171 (72%) patients had CAP ≥ 248dB/m (ie hepatic steatosis), whereas 83 (21%) patients had LSM ≥ 7.0/6.2 kPa (M/XL probes) (significant liver fibrosis). CAP was not associated with any macro/microvascular complications, whereas LSM ≥ 7.0/6.2 kPa was independently associated with prior cardiovascular disease (adjusted OR 3.3, 95%CI 1.2-8.8; P = .02) and presence of microvascular complications (adjusted OR 4.2, 95%CI 1.5-11.4; P = .005), mainly CKD (adjusted OR 3.6, 95%CI 1.3-10.1; P = .01) and retinopathy (adjusted OR 3.7, CI 95% 1.2-11.9; P = .02). Neither diabetes duration nor haemoglobin A1c differed according to CAP or LSM values., Conclusion: Significant fibrosis, detected by FibroScan ® , is independently associated with increased prevalence of macrovascular and microvascular complications, thus opening a new scenario in the use of this tool for a comprehensive evaluation of hepatic and vascular complications in patients with T2DM., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

48. [A complicated case of purulent pericarditis secondary to pneumonia].

Author

Casella F, Pisano G, Bossi I, Cogliati C, and Montano N

Subjects
Aged, Female, Humans, Pericarditis diagnosis, Suppuration, Pericarditis etiology, Pneumonia complications
Abstract

Purulent pericarditis in the antibiotic era has become an uncommon entity. It is typically an acute illness with a high mortality (about 30%) related to cardiac tamponade, a complication that accounts for 42-77% of cases. Few cases of purulent pericarditis associated with tamponade have been published in the literature. In this paper we describe a complicated case of purulent pericarditis secondary to left pneumonia. In particular, we emphasize the importance of early recognition, prompt institution of appropriate antibiotic therapy and early drainage for survival.

Published
2008

49. [Prevention and control of respiratory tract infections in the network of Italian Centers for Cystic Fibrosis].

Author

Festini F, Ballarin S, Loganes C, Codamo T, Doro R, Adamo A, Adorni R, Cucci M, Di Marco F, Lovallo R, Omenetti S, Panebianco R, Pisano G, Russo A, Sciabacucchi MC, and Zunino ML

Subjects
Adult, Air Microbiology, Child, Cystic Fibrosis therapy, Disinfectants administration & dosage, Hand Disinfection, Humans, Italy, Patient Isolation, Practice Guidelines as Topic, Respiratory Therapy, Respiratory Tract Infections microbiology, Surveys and Questionnaires, Cystic Fibrosis complications, Respiratory Tract Infections prevention & control
Abstract

Infections caused by respiratory pathogens such as Burkholderia cepacia and Pseudomonas aeruginosa are associated with an increased morbidity and mortality in people affected by cystic fibrosis, the most common lethal genetic disease in Caucasian populations. Preventing the acquisition of these pathogens is paramount for these patients. The goal of this survey was to assess the distribution and the prevalence of the measures adopted for the prevention and control of infections caused by respiratory pathogens in the 28 italian centres for cystic fibrosis. 21 questionnaires were returned and some important differences can be observed in the adoption of segregation measures. Although results may be influenced by other factors, specific segregation policies appear to be more directly associated than other measures (e.g., intensive disinfection; behavioural rules to minimise patient' contacts) with lower prevalence of Pseudomonas aeruginosa (OR 0.36 CI95% 0.31-0.42), of multidrug-resistant Pseudomonas aeruginosa (OR 0.30 CI95% 0.22-0.40), and of methicillin-resistant Staphylococcus aureus (OR 0.67 CI95% 0.48-0.94).

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results